Alpha 2.0
Login Register
» Authors » Marie-Aude Khuong-Josses

Marie-Aude Khuong-Josses

Explore the profile of Marie-Aude Khuong-Josses including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 654
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Science
Top 10 Co-Authors
Sophie Abgrall
Pierre De Truchis
Dominique Costagliola
Sophie Matheron
Juliette Pavie
Odile Launay
Jacques Gilquin
Anne Simon
Daniel Podzamczer
Aba Mahamat
Published In
J Acquir Immune Defic Syndr
PLoS One
Lancet
Clin Infect Dis
HIV Clin Trials
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study
Smith G, Henry W, Podzamczer D, Masia M, Bettacchi C, Arasteh K, et al.
Open Forum Infect Dis . 2021 Sep; 8(9):ofab439. PMID: 34557563
Background: In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase 2b study, long-acting (LA) injectable cabotegravir + rilpivirine dosed every 8 weeks (Q8W) or every 4 weeks (Q4W) demonstrated...
2.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Overton E, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al.
Lancet . 2020 Dec; 396(10267):1994-2005. PMID: 33308425
Background: Phase 3 clinical studies showed non-inferiority of long-acting intramuscular cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important phase 2 results of every 8 weeks dosing,...
3.
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials
van Wyk J, Orkin C, Rubio R, Bogner J, Baker D, Khuong-Josses M, et al.
J Acquir Immune Defic Syndr . 2020 Jul; 85(3):325-330. PMID: 32675772
Background: The SWORD trials showed that in participants who achieved virologic suppression taking 3-drug or 4-drug regimens, switching to the 2-drug regimen dolutegravir plus rilpivirine was noninferior in maintaining HIV-1...
4.
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
Murray M, Antela A, Mills A, Huang J, Jager H, Bernal E, et al.
AIDS Behav . 2020 May; 24(12):3533-3544. PMID: 32447500
The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized...
5.
Treatment as prevention (TasP) and perceived sexual changes in behavior among HIV-positive persons: a French survey in infectious diseases departments in Paris
Couffignal C, Papot E, Etienne A, LeGac S, Laouenan C, Beres D, et al.
AIDS Care . 2019 Aug; 32(7):811-817. PMID: 31431047
We evaluated awareness of treatment as prevention (TasP) among adults people living with HIV (PLHIV) in five infectious disease departments in Paris, then how they perceived its impact on their...
6.
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies
Aboud M, Orkin C, Podzamczer D, Bogner J, Baker D, Khuong-Josses M, et al.
Lancet HIV . 2019 Jul; 6(9):e576-e587. PMID: 31307948
Background: Primary analyses of the SWORD-1 and SWORD-2 trials at 48 weeks showed that switching to a two-drug regimen of dolutegravir plus rilpivirine was non-inferior to continuing a standard three-drug...
7.
Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France
de Monteynard L, Matheron S, Grabar S, De Truchis P, Gilquin J, Pavie J, et al.
PLoS One . 2018 Nov; 13(10):e0205385. PMID: 30379870
Background: The influence of geographic origin on the risk of severe illness and death on cART has not been explored in European countries. Method: We studied antiretroviral-naïve heterosexual HIV-1-infected individuals...
8.
Risk of Progressive Multifocal Leukoencephalopathy in the Combination Antiretroviral Therapy Era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4)
Melliez H, Mary-Krause M, Bocket L, Guiguet M, Abgrall S, De Truchis P, et al.
Clin Infect Dis . 2018 Apr; 67(2):275-282. PMID: 29635465
Background: Risk factors for progressive multifocal leukoencephalopathy (PML) in individuals with human immunodeficiency virus (HIV) infection are poorly documented in the era of combination antiretroviral therapy (cART). Methods: We studied...
9.
Influence of geographic origin, sex, and HIV transmission group on the outcome of first-line combined antiretroviral therapy in France
de Monteynard L, Matheron S, Gilquin J, Pavie J, De Truchis P, Grabar S, et al.
AIDS . 2016 Jul; 30(14):2235-46. PMID: 27428741
Background: More data are needed on the influence of geographic origin, sex, and the HIV transmission group on biological and clinical outcomes after first-line combined antiretroviral therapy (cART) initiation. Methods:...
10.
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial
Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses M, et al.
J Acquir Immune Defic Syndr . 2015 Aug; 70(5):515-9. PMID: 26262777
The SINGLE study was a randomized, double-blind, noninferiority study that evaluated the safety and efficacy of 50 mg dolutegravir + abacavir/lamivudine versus efavirenz/tenofovir/emtricitabine in 833 ART-naive HIV-1 + participants. Of...